BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang GY, Zhang XY, Wang CJ, Guan YF. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies. World J Gastroenterol 2023; 29(1): 75-95 [PMID: 36683713 DOI: 10.3748/wjg.v29.i1.75] [Reference Citation Analysis]
2 Grapentine S, Agarwal P, Dolinsky V, Bakovic M. Phosphoethanolamine reverses aberrant DNA methylation in non-alcoholic steatohepatitis caused by Pcyt2 deficiency.. [DOI: 10.21203/rs.3.rs-2143064/v1] [Reference Citation Analysis]
3 Liu F, Wei L, Leow WQ, Liu S, Ren Y, Wang X, Li X, Rao H, Huang R, Wu N, Wee A, Zhao J. Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis. Front Med 2022;9:925357. [DOI: 10.3389/fmed.2022.925357] [Reference Citation Analysis]
4 Alshehade S, Alshawsh MA, Murugaiyah V, Asif M, Alshehade O, Almoustafa H, Al Zarzour RH. The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions. Life Sci 2022;:120732. [PMID: 35760093 DOI: 10.1016/j.lfs.2022.120732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu HE, Guo JS. All about NASH: disease biology, targets, and opportunities on the road to NASH drugs. Acta Pharmacol Sin 2022;43:1101-2. [PMID: 35379932 DOI: 10.1038/s41401-022-00900-y] [Reference Citation Analysis]
6 Cabiati M, Gaggini M, De Simone P, Del Ry S. Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression. Clin Exp Metastasis 2022. [PMID: 35429302 DOI: 10.1007/s10585-022-10164-9] [Reference Citation Analysis]